No predictive markers for chemotherapy activity have been validated in gastric cancer (GC). The potential value of class III β-tubulin (TUBB3) as biomarker for prognosis and resistance to taxane-based therapy was reported.
Methods:
We analyzed GC samples of patients enrolled in the Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach (ITACA-S), a randomized adjuvant study comparing 5-fluorouracil/leucovorin (5-FU/LV) and docetaxel-based sequential chemotherapy. TUBB3 was quantitated by selected reaction monitoring mass spectrometry and patients were stratified using a threshold of 750 attomoles per microgram (amol/µg). Cox proportional modeling and Kaplan-Meier survival analysis were used to assess the impact of TUBB3 expression on overall survival (OS) and disease-free survival.
Results:
Patients with TUBB3 protein levels >750 and <750 amol/µg were 21.9% and 78.1%, respectively, and were well-balanced between treatment arms. TUBB3 protein levels were not prognostic. Whereas no survival differences according to the 2 arms were observed in the subgroup with low TUBB3 expression (5-year OS 47% vs 40%; p = 0.44), patients with high TUBB3 had a clinically meaningful poorer OS when receiving docetaxel-based versus 5-FU/LV chemotherapy (5-year OS 31% vs 54%; p = 0.09), with a statistically significant interaction between TUBB3 and treatment (p = 0.049).
Conclusions:
The quantification of TUBB3 might be considered as a negative predictive biomarker of benefit from taxane-based therapy in GC. Studies are needed to evaluate its role in the neoadjuvant setting.
FerlayJSoerjomataramIErvikM, et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase no. 11, http://globocan.iarc.fr (2013, accessed 15 October 2018).
2.
SongunIPutterHKranenbargEM, et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol2010; 11: 439–449.
3.
PietrantonioFDe BraudFDa PratV, et al. A review on biomarkers for prediction of treatment outcome in gastric cancer. Anticancer Res2013; 33: 1257–1266.
4.
RaimondiANichettiFPeverelliG, et al. Genomic markers of resistance to targeted treatments in gastric cancer: Potential new treatment strategies. Pharmacogenomics2018; 19: 1047–1068.
5.
DavidsonMCafferkeyCGoodeEF, et al. Survival in advanced esophagogastric adenocarcinoma improves with use of multiple lines of therapy: results from an analysis of more than 500 patients. Clin Colorectal Cancer2018; 17: 223–230.
6.
MiceliRTomaselloGBregniG, et al. Adjuvant chemotherapy for gastric cancer: current evidence and future challenges. World J Gastroenterol2014; 20: 4516–4525.
7.
CaiolaEBrogginiMMarabeseM. Genetic markers for prediction of treatment outcomes in ovarian cancer. Pharmacogenomics J2014; 14: 401–410.
8.
NobleRLBeerCTCuttsJH. Role of chance observations in chemotherapy: vinca rosea. Ann N Y Acad Sci1958; 76: 882–894.
9.
StantonRAGernertKMNettlesJH, et al. Drugs that target dynamic microtubules: a new molecular perspective. Med Res Rev2011; 31: 443–481.
10.
PerezEA. Microtubule inhibitors: differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. Mol Cancer Ther2009; 8: 2086–2095.
11.
IzutsuNMaesawaCShibazakiM, et al. Epigenetic modification is involved in aberrant expression of class III beta-tubulin, TUBB3, in ovarian cancer cells. Int J Oncol2008; 32: 1227–1235.
12.
LiZQingYGuanW, et al. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy. Cancer Chemother Pharmacol2014; 74: 777–786.
13.
MozzettiSFerliniCConcolinoP, et al. Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res2005; 11: 298–305.
14.
PloussardGTerrySMailleP, et al. Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy. Cancer Res2010; 70: 9253–9264.
15.
ReimanTLaiRVeillardAS, et al. Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials. Ann Oncol2012; 23: 86–93.
16.
WangJShaoJShenH, et al. TUBB3 as molecular marker for improved taxane efficacy of adjuvant chemotherapy for breast cancer. Int J Clin Exp Med2016; 9: 3765–3769.
17.
SevePMackeyJIsaacS, et al. Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther2005; 4: 2001–2007.
18.
KohYKimTMJeonYK, et al. Class III beta-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma. Ann Oncol2009; 20: 1414–1419.
19.
HwangJEHongJYKimK, et al. Class III beta-tubulin is a predictive marker for taxane-based chemotherapy in recurrent and metastatic gastric cancer. BMC Cancer2013; 13: 431.
20.
MoiseyenkoVMVolkovNMSuspistinEN, et al. Evidence for predictive role of BRCA1 and bTUBIII in gastric cancer. Med Oncol2013; 30: 545.
21.
UranoNFujiwaraYDokiY, et al. Clinical significance of class III beta-tubulin expression and its predictive value for resistance to docetaxel-based chemotherapy in gastric cancer. Int J Oncol2006; 28: 375–381.
22.
GaoJLuMYuJW, et al. Thymidine phosphorylase/beta-tubulin III expressions predict the response in Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel. BMC Cancer2011; 11: 177.
23.
LuMGaoJWangXC, et al. Expressions of thymidylate synthase, thymidine phosphorylase, class III beta-tubulin, and excision repair cross-complementing group 1predict response in advanced gastric cancer patients receiving capecitabine plus paclitaxel or cisplatin. Chin J Cancer Res2011; 23: 288–294.
24.
YuJGaoJLuZ, et al. Combination of microtubule associated protein-tau and beta-tubulin III predicts chemosensitivity of paclitaxel in patients with advanced gastric cancer. Eur J Cancer2014; 50: 2328–2335.
25.
GalmariniCMTreilleuxICardosoF, et al. Class III beta-tubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxel. Clin Cancer Res2008; 14: 4511–4516.
26.
HuangZLCaoXLuoRZ, et al. Analysis of ERCC1, BRCA1, RRM1 and TUBB3 as predictors of prognosis in patients with non-small cell lung cancer who received cisplatin-based adjuvant chemotherapy: a prospective study. Oncol Lett2016; 11: 299–305.
27.
SevePDumontetC. Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents?Lancet Oncol2008; 9: 168–175.
28.
MarianiMShahabiSSieberS, et al. Class III beta-tubulin (TUBB3): more than a biomarker in solid tumors?Curr Mol Med2011; 11: 726–731.
29.
KimYJSweetSMEgertsonJD, et al. Data-independent acquisition mass spectrometry to quantify protein levels in FFPE tumor biopsies for molecular diagnostics. J Proteome Res2019; 18: 426–435.
30.
BajettaEFlorianiIDi BartolomeoM, et al. Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer. Ann Oncol2014; 25: 1373–1378.
31.
Di BartolomeoMPietrantonioFPellegrinelliA, et al. Osteopontin, E-cadherin, and beta-catenin expression as prognostic biomarkers in patients with radically resected gastric cancer. Gastric Cancer2016; 19: 412–420.
32.
HembroughTThyparambilSLiaoWL, et al. Application of selected reaction monitoring for multiplex quantification of clinically validated biomarkers in formalin-fixed, paraffin-embedded tumor tissue. J Mol Diagn2013; 15: 454–465.
33.
PatelVHoodBLMolinoloAA, et al. Proteomic analysis of laser-captured paraffin-embedded tissues: a molecular portrait of head and neck cancer progression. Clin Cancer Res2008; 14: 1002–1014.
34.
CatenacciDVLiaoWLThyparambilS, et al. Absolute quantitation of met using mass spectrometry for clinical application: assay precision, stability, and correlation with MET gene amplification in FFPE tumor tissue. PLoS One2014; 9: e100586.
35.
McShaneLMHayesDF. Publication of tumor marker research results: the necessity for complete and transparent reporting. J Clin Oncol2012; 30: 4223–4232.
36.
SevePLaiRDingK, et al. Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10. Clin Cancer Res2007; 13: 994–999.
37.
KavallarisMBurkhartCAHorwitzSB. Antisense oligonucleotides to class III beta-tubulin sensitize drug-resistant cells to taxol. Br J Cancer1999; 80: 1020–1025.
38.
KamathKWilsonLCabralF, et al. BetaIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability. J Biol Chem2005; 280: 12902–12907.
39.
FreidlinBMcShaneLMKornEL. Randomized clinical trials with biomarkers: design issues. J Natl Cancer Inst2010; 102: 152–160.
40.
SimonRMPaikSHayesDF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst2009; 101: 1446–1452.
41.
TokiMCecchiFHembroughT, et al. PS01.30: Domain-specific c-met measurement by quantitative immunofluorescence and mass spectrometry in non-small cell lung cancer: topic: pathology. J Thorac Oncol2016; 11: S287.
42.
SteinerCTilleJCLamerzJ, et al. Quantification of HER2 by targeted mass spectrometry in formalin-fixed paraffin-embedded (FFPE) breast cancer tissues. Mol Cell Proteomics2015; 14: 2786–2799.
43.
AnEOckCYKimTY, et al. Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment. Ann Oncol2017; 28: 110–115.
44.
NuciforoPThyparambilSAuraC, et al. High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy. Mol Oncol2016; 10: 138–147.
45.
Al-BatranSEPauligkCHomannN, et al. LBA-008Docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) as perioperative treatment of resectable gastric or gastro-esophageal junction adenocarcinoma: the multicenter, randomized phase 3 FLOT4 trial (German Gastric Group at AIO). Ann Oncol2017; 28 (suppl 3): 10.1093/annonc/mdx302.007.
46.
CunninghamDAllumWHStenningSP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med2006; 355: 11–20.
47.
FordHEMarshallABridgewaterJA, et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol2014; 15: 78–86.
48.
ShiJGaoPSongY, et al. Efficacy and safety of taxane-based systemic chemotherapy of advanced gastric cancer: a systematic review and meta-analysis. Sci Rep2017; 7: 5319.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
